Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Abstract

In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-DKD ClinicalTrials.gov number, NCT02540993.).

Keywords

Type 2 diabetesMedicineKidney diseaseDiabetes mellitusDiseaseMEDLINEInternal medicineIntensive care medicineEndocrinologyPolitical science

MeSH Terms

AgedAlbuminuriaCreatinineDiabetes MellitusType 2Diabetic NephropathiesDouble-Blind MethodFemaleGlomerular Filtration RateHumansHyperkalemiaMaleNaphthyridinesRenal InsufficiencyChronicTreatment Outcome

Affiliated Institutions

Related Publications

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J.L. Heerspink , Bergur V. Stefánsson , Ricardo Correa‐Rotter +11 more

Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50...

2020 New England Journal of Medicine 4549 citations

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Vlado Perkovic , Meg Jardine , Bruce Neal +21 more

In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a med...

2019 New England Journal of Medicine 5513 citations

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies , David A. D’Alessio , Judith Fradkin +7 more

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on...

2018 Diabetes Care 3378 citations

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott , Itamar Raz , Marc P. Bonaca +17 more

In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MAC...

2018 New England Journal of Medicine 5890 citations

Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum

William T. Cefalu , John B. Buse , Jaakko Tuomilehto +8 more

The International Diabetes Federation estimates that 415 million adults worldwide now have diabetes and 318 million have impaired glucose tolerance. These numbers are expected t...

2016 Diabetes Care 144 citations

Publication Info

Year: 2020
Type: article
Volume: 383
Issue: 23
Pages: 2219-2229
Citations: 2232
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2232

OpenAlex

143

Influential

2049

CrossRef

Cite This

APA Style

                            
                                
                                    George L. Bakris, 
                                
                                    Rajiv Agarwal, 
                                
                                    Stefan D. Anker
                                
                                et al.
                            
                            (2020). 
                            Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. 
                            New England Journal of Medicine
                            , 383
                            (23)
                            , 2219-2229.
                            https://doi.org/10.1056/nejmoa2025845
                        

Identifiers

DOI: 10.1056/nejmoa2025845
PMID: 33264825

Data Quality

Data completeness: 90%